Cytologic and Histologic Features of Primary Mucinous Adenocarcinoma of Skin in the Axilla

Kotru, Mrinalini; Manucha, Varsha; Singh, Usha

doi:10.1159/000325797

Cited by 13 publications

(28 citation statements)

References 10 publications

(20 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4 On FNAC, nests of tumor cells with eccentrically placed nuclei were seen in the background of mucin. Similar cytologic findings were first described in the literature by Kotru et al 5 Histologically, dermis shows individual malignant cells rich in glycogen that stain with PAS and are diastase sensitive. The glandular features are a narrow lumen surrounded by a layer of flat or cuboidal cells.…”

Section: Discussionsupporting

confidence: 86%

Primary Mucinous Eccrine Adenocarcinoma of the Scalp

Bannur

Mastiholimath²,

Malur³

2009

Acta Cytologica

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 86%

Primary Mucinous Eccrine Adenocarcinoma of the Scalp

Bannur

Mastiholimath²,

Malur³

2009

Acta Cytologica

View full text Add to dashboard Cite

“…Other malignancies aside from breast carcinoma have also been reported to occur in the axilla, including extramammary Paget's disease and basal cell carcinoma . Other neoplasms reported to occur in the axilla include primary mucinous carcinoma of skin, primary cutaneous adenoid cystic carcinoma, primary cutaneous B‐cell lymphoma, atypical post‐radiation vascular lesions, dermatomyofibroma and sebaceous carcinoma …”

Section: Discussionmentioning

confidence: 99%

Primary signet‐ring cell carcinoma of the axilla

et al. 2012

View full text Add to dashboard Cite

Primary cutaneous histiocytoid or signet-ring cell carcinoma represents an extremely rare adnexal neoplasm that most frequently presents on the eyelid but more rarely may present in the axilla. As this tumor can resemble metastatic carcinoma with signet-ring cells, especially lobular carcinoma of the breast, it can often present a diagnostic challenge. We present a case of cutaneous signet-ring cell carcinoma presenting in the axilla and outline the challenges of diagnosing this rare malignancy.

show abstract

“…Finally, there are a few examples regarding a connection between amyloids and tumorigenesis. One, the formation of intracellular amyloid fibers in Bence Jones ‐type myeloma,48 the directly related to HPV: a localized amyloidosis in endometrioid adenocarcinoma,49 and recently, the report of an amyloid‐like form of 16E1E4 which explains its accumulation during productive infection and its effect on cellular integrity50. What is becoming clear is that at least 4 human genes appear to have a dual role: 1 in amyloid related neurodegeneration and the other in cell‐cycle control, where both roles are proposed to be the 2 sides of the same coin 51…”

Section: Discussionmentioning

confidence: 99%

Hepatic stellate cell proliferation: A potential role of protein kinase R

et al. 2011

View full text Add to dashboard Cite

We read with great interest the article by Martinot-Peignoux et al. 1 In this report from France, undetectable serum hepatitis C virus (HCV) RNA at 12 weeks (Wþ12) (409 patients) post-treatment follow-up was as relevant as undetectable serum HCV RNA at 24 weeks (Wþ24) (sustained virological response [SVR]; 408 patients) after the end of treatment.Current standard therapy is based on a combination of pegylated interferon (PEG-IFN) and ribavirin, but it leads to only $50% SVR in patients with HCV genotype 1 and high viral loads. 2 IFN reduced the risk for HCC, especially among patients with SVR. 3,4 Then, we need to accurately judge whether the patient is SVR or non-SVR, applying the present standard for the judgment of SVR with the undetectability of serum HCV RNA at post-treatment Wþ24.We investigated 102 patients with chronic hepatitis C genotype 1 treated with PEG-IFN-alfa 2a plus ribavirin for 48 weeks. Some of these patients had already been included in previous reports. 5,6 Serum HCV RNA was measured using the COBAS TaqMan HCV test with a detection limit of 1.2 logIU/mL. At the Wþ24 posttreatment follow-up, 40 (39.2%) patients had SVR, and 31 (48.4%) and 9 (23.6%) were treatment naïve and previously treated patients, respectively. At Wþ12, serum HCV RNA was undetectable in 42 patients, and 40 patients were SVR (PPV, 95.2%). We found two relapsers at Wþ24 (undetectable at Wþ12).In the case of using direct-acting antivirals, earlier knowledge of treatment outcome would be useful for retreatment for the same patient. Taken together, our findings show that Wþ12 undetectable serum HCV RNA is not suitable for predicting persistent virological response. Further understanding of the mechanism of relapse could be useful in reducing the posttreatment follow-up period from the current standard of 24 weeks. Reply:We read, with interest, the letter by Kanda et al. regarding our article. As you know, the primary end-point of antiviral therapy for chronic hepatitis C virus (HCV) is achieving sustained virological response (SVR), defined as undetectable HCV-RNA in serum 24 weeks after stopping antiviral therapy. SVR is equivalent to viral eradication and is associated with a reduction in the risk of cirrhosis and hepatocellular carcinoma. 1 Recently, it has been proposed that a 12-week post-treatment follow-up might be as relevant as 24 weeks to determine the SVR in patients with HCV receiving pegylated-interferon (PEG-IFN) and ribavirin. 2 In our study, 573 patients who received combination PEG-IFN and ribavirin and had a virological response at the end of treatment were evaluated. Serum HCV-RNA was measured, using a new assay based on transcription-mediated amplification (TMA), with a lowest detection limit of 5-10 IU/mL, at week (W)þ12 and Wþ24 after the end of treatment. At the Wþ24 post-treatment follow-up, 408 (71%) patients had an SVR, 181 (71.2%) were treated with PEG-IFN alpha-2a and ribavirin, and 227 (71.1%) were treated with PEG-IFN alpha-2b and ribavirin. At Wþ12, serum HCV-RNA was undetectable in 409 pati...

show abstract

Cytologic and Histologic Features of Primary Mucinous Adenocarcinoma of Skin in the Axilla

Cited by 13 publications

References 10 publications

Primary Mucinous Eccrine Adenocarcinoma of the Scalp

Primary Mucinous Eccrine Adenocarcinoma of the Scalp

Primary signet‐ring cell carcinoma of the axilla

Hepatic stellate cell proliferation: A potential role of protein kinase R

Contact Info

Product

Resources

About